Search company, investor...

PharMEDium Healthcare Holdings

pharmedium.com

Founded Year

1992

Stage

Dead | Dead

About PharMEDium Healthcare Holdings

PharMEDium Healthcare Holdings is a provider of customized outsourced CSPs that meet specific hospital and physician clinical needs and quality standards in formulations that are not otherwise commercially available.

Headquarters Location

Two Conway Park 150 North Field Drive, Suite 350

Lake Forest, Illinois, 60045,

United States

800-523-7749

Missing: PharMEDium Healthcare Holdings's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: PharMEDium Healthcare Holdings's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

PharMEDium Healthcare Holdings Patents

PharMEDium Healthcare Holdings has filed 40 patents.

The 3 most popular patent topics include:

  • Car classifications
  • Electronic health records
  • Fluid dynamics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/25/2019

12/10/2019

Car classifications, Medical terminology, Fluid dynamics, Healthcare occupations, Electronic health records

Grant

Application Date

6/25/2019

Grant Date

12/10/2019

Title

Related Topics

Car classifications, Medical terminology, Fluid dynamics, Healthcare occupations, Electronic health records

Status

Grant

Latest PharMEDium Healthcare Holdings News

AmerisourceBergen Completes Acquisition of PharMEDium Healthcare Holdings, Inc.

Nov 6, 2015

AmerisourceBergen Completes Acquisition of PharMEDium Healthcare Holdings, Inc. November 06, 2015 12:26 PM Eastern Standard Time VALLEY FORGE, Pa.--( BUSINESS WIRE )--AmerisourceBergen Corporation (NYSE:ABC) today announced that it has completed the acquisition of PharMEDium Healthcare Holdings, Inc., the privately held leading national provider of outsourced compounded sterile preparations (CSPs) to acute care hospitals in the United States, from Clayton, Dubilier & Rice for $2.575 billion in cash, subject to certain adjustments and on a cash-free, debt-free basis. As previously disclosed, the Company has included a $0.22 to $0.26 net contribution from PharMEDium in its expectations for adjusted earnings per share in fiscal 2016 to be in the range of $5.73 to $5.90. The Company continues to expect to generate approximately $30 million in synergies by fiscal 2018. About AmerisourceBergen AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel in human and animal health. With over $135 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 17,000 people. AmerisourceBergen is ranked #16 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com . AmerisourceBergen's Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "will," "project," "intend," "plan," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and change in circumstances. These statements are not guarantees of future performance and are based on assumptions that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: competition; industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in pharmaceutical market growth rates; price inflation in branded and generic pharmaceuticals, and price deflation in generics; declining economic conditions in the United States and abroad; financial market volatility and disruption; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; the loss, bankruptcy or insolvency of a major supplier; changes to the customer or supplier mix; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; interest rate and foreign currency exchange rate fluctuations; the disruption of AmerisourceBergen's cash flow and ability to return value to its stockholders in accordance with its past practices; risks associated with the strategic, long-term relationship between Walgreen Boots Alliance, Inc. and AmerisourceBergen, including with respect to the pharmaceutical distribution agreement and/or the global sourcing joint venture; risks associated with the potential impact on AmerisourceBergen's earnings per share resulting from the issuance of the warrants to subsidiaries of Walgreen Boots Alliance, Inc. (the "Warrants"); AmerisourceBergen's inability to implement its hedging strategy to mitigate the potentially dilutive effect of the issuance of its common stock in accordance with the Warrants under its special share repurchase program due to its financial performance, the current and future share price of its common stock, its expected cash flows, competing priorities for capital, and overall market conditions; changes in the United States healthcare and regulatory environment; increasing governmental regulations regarding the pharmaceutical supply channel and pharmaceutical compounding; federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; federal and state prosecution of alleged violations of related laws and regulations, and any related litigation, including shareholder derivative lawsuits or other disputes relating to our distribution of controlled substances; increased federal scrutiny and qui tam litigation for alleged violations of fraud and abuse laws and regulations and/or any other laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services and any related litigation; material adverse resolution of pending legal proceedings; declining reimbursement rates for pharmaceuticals; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, including the integration of MWI and PharMEDium, or the ability to capture all of the anticipated synergies related thereto; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic sanctions and import laws and regulations; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; changes in tax laws or legislative initiatives that could adversely affect AmerisourceBergen's tax positions and/or AmerisourceBergen's tax liabilities or adverse resolution of challenges to AmerisourceBergen's tax positions; natural disasters or other unexpected events that affect AmerisourceBergen's operations; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting AmerisourceBergen's business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors) and Item 1 (Business) in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2014 and elsewhere in that report and (ii) in other reports filed with the Securities and Exchange Commission. Contacts

PharMEDium Healthcare Holdings Frequently Asked Questions (FAQ)

  • When was PharMEDium Healthcare Holdings founded?

    PharMEDium Healthcare Holdings was founded in 1992.

  • Where is PharMEDium Healthcare Holdings's headquarters?

    PharMEDium Healthcare Holdings's headquarters is located at Two Conway Park, Lake Forest.

  • What is PharMEDium Healthcare Holdings's latest funding round?

    PharMEDium Healthcare Holdings's latest funding round is Dead.

  • Who are the investors of PharMEDium Healthcare Holdings?

    Investors of PharMEDium Healthcare Holdings include AmerisourceBergen, Clayton, Dubilier & Rice, Oak Investment Partners and Baird Venture Partners.

  • Who are PharMEDium Healthcare Holdings's competitors?

    Competitors of PharMEDium Healthcare Holdings include Pharmaca Integrative Pharmacy, RxStrategies, IntegriChain, Remedi Seniorcare, Millennium Pharmacy Systems and 7 more.

Compare PharMEDium Healthcare Holdings to Competitors

A
Apex Pharmacies

Apex Pharmacies Ltd. was founded in 2004. The Apex business plan involves bringing together experienced pharmacy operators with financial professionals and ensuring access to capital. Apex will acquire highly sought after pharmacy targets in Western Canada at a pace that aims to allow integration of these acquisitions into the overall Apex chain, while maintaining strong bottom line performance. www.apexpharmacies.com .

IntegriChain Logo
IntegriChain

IntegriChain is a channel management cloud used by life sciences suppliers, including nine of the top 10 pharmaceutical manufacturers, to drive channel collaboration and to improve the efficiency of how products reach customers. Pharmaceutical, biopharm/specialty pharma, generics, and consumer health suppliers use IntegriChain to manage their supply chain relationships, inventories, and orders across a vast network of retailers, ecommerce, and distributors. As a suite of informed applications and analytics built on top of aggregated channel inventory and point-of-sale (POS) data, IntegriChain provides customer operations, national accounts, and finance teams with a collaborative, agile, and mobile alternative to ERP and homegrown systems.

Remedi Seniorcare Logo
Remedi Seniorcare

Remedi SeniorCare delivers comprehensive pharmacy services, pharmacy consulting, and data management services to nursing homes, assisted living, and continuing care retirement communities. The business is committed to helping these organizations achieve outstanding care, financial strength, and medication safety. Remedi combines their culture of caring with real-world pharmacy services and best-in-class technology to give organizations more time and resources and help them focus on caring for their residents.

R
RxStrategies

RxStrategies is a provider of discounted prescription medicines.

S
SFJ Pharmaceuticals

SFJ Pharmaceuticals is a Specialty Pharma Company deploying a new business model for the clinical development and registration of pharmaceutical products. SFJ Pharmaceuticals provides a financially advantageous and creative alternative approach to partnering. The comapny can provide the strategic financing, clinical development and regulatory resources for the clinical development and approval of products. SFJ Pharmaceuticals is staffed with a seasoned team of professionals, with extensive experience in the clinical development and regulatory approval of pharmaceutical products.

F
ForHealth Technologies

ForHealth Technologies is a manufacturer of pharmacy-based systems that aim to automate the preparation of sterile, intravenous medications.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.